Applications published 24 October 2007

Pharmaceutical compsn for improving palatability of drugs and process for preparation thereof
Council of Scientific and Industrial Research 1845937*

Methods and related compsns for reduction of fat and skin tightening
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Centre 1845938*

• Drug delivery materials made by sol/gel technology
Cinvention 1845939*

• Syrup compsn comprising dexibupropen as an active ingredient and method for the preparation thereof
Hanmi Pharm 1845941*

• GNRH analogue formulations
Camarus; Goddard, Christopher 1845942*

• Nano- and mesosized particles comprising an inorganic core, process and applications thereof
Ben Gurion University of the Negev Research and Development Authority 1845943*

• Pharmaceutical compsns
ID Biomedical Corp of Quebec c.o.b. as GlaxoSmithKline Biologicals North America 1845944*

• Process for the preparation of dosage forms comprising a solid dispersion of a microcrystalline active agent
Abbott 1845945*

• Pharmaceutical compsns useful in the transmucosal administration of drugs
Orexo 1845946*

• Fast-disintegrating microporous binder and process for making it
Pfizer 1845947*

• Colonic delivery of active agents
DA Volterra; Centre National de la Recherche Scientifique 1845948*

• Melt granulation of a compsn containing a calcium-containing compound
Nycomed Pharma 1845949*

• Fast wet-massing method for the preparation of calcium-containing compsns
Nycomed Pharma 1845950*

• Embolisation using poly-4-hydroxybutyrate particles
Tepha 1845951*

• Stable tablet formulation of tetrahydrobiopterin
Biomarin Pharmaceuticals 1845952*

• Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of HMG-CoA reductase inhibitors
Pfizer Products 1845953*

• Orally disintegrating compsn of olanzapine or donepezil
KRKA 1845954*

• Method for the production of a tamper-proof form of administration
Gruenenthal 1845955*

• Break-resistant delayed-release forms of administration
Gruenenthal 1845956*

• Method for producing a drug extract that contains hydroxystilbene
Heger, Peter; Rettenberger, Reinhard; Spaich, Carl-Friedrich 1845957*

• Anti-misuse microparticulate oral drug form
Flamel Technologies 1845958*

• Medicament that is intended for oral adminstration, comprising a cyclooxygenase-2 inhibitor, and preparation method thereof
Vetoquinol 1845959*

• Prevention and treatment of thromboembolic disorders
Bayer HealthCare 1845961*

• Use of active ingredients containing hydroxystilbene for preventing and/or treating osteoporosis
Heger, Peter; Rettenberger, Reinhard; Spaich, Carl-Friedrich 1845962*

• Isolation of N-butylbenzenesulphonamide, synthesis of benzenesulphonamide derivatives, and use of N-butylbenzenesuphonamide and benzenesulphonamide derivatives for the treatment of benign prostate hyperplasia and/or prostate carcinoma
LTS Lohmann Therapie-Systeme 1845963*

• Antimicrobial compsns comprising a natural agent selected from gallic acid, eucalyptol, naringin, a jasmonic acid compound and any combination thereof
Kimberley-Clark Worldwide 1845964*

• Adapalene for the long-term treatment of acne vulgaris
Galderma Research & Development 1845965*

• Antineoplastic preparation and the use of antineoplastic preparation
SGP & Sons; Kandefer-Szerszen. Martyna; Rzeski, Wojciech; Pierzynowski, Stefan 1845966*

• A method of modulating T-cell functioning
The Board of Trustees of Leland Stanford Junior University 1845967*

• Compsn comprising an NMDA receptor antagonist and levodopa and use thereof for treating neurological disease
Neuromolecular Pharmaceuticals 1845968*

• Compsns and methods relating to mitochondrial hyperpolarisation in neurological disease
University of Rochester 1845969*

• Tumour necrosis factor inhibitors
Ception Therapeutics; Trustees of the University of Pennsylvania 1845970*

• A method of treating cellular damage
Medvet Science 1845971*

• Novel heteropyrrole analogues acting on cannabinoid receptors
University of Connecticut 1845972*

• Pharmaceutical compounds
Astex Therapeutics 1845973*

• Pharmaceutical compounds
Astex Therapeutics 1845974*

• Combinations of pyrazole kinase inhibitors and further antitumour agents
Astex Therapeutics 1845975*

• Use of inhibitors of soluble epoxide hydrolase to synergise activity of COX and 5-LOX inhibitors
The Regents of the University of California 1845976*

• Oral dosage form comprising rosiglitazone
SB Pharma Puerto Rico 1845977*

• Substituted pyrazolo-pyridines, compsns containing them, method for the production thereof, and their use
Aventis Pharma 1845978*

• Methods and compsns for decreasing saliva production
Neurohealing Pharmaceuticals 1845979*

• Aqueous gel formulations containing 1-(2-methylpropyl)-1H-imidazo[4,5-C]{1,5]naphthyridin-4-amine
Takeda Pharmaceutical Company 1845980*

• Synthesis of sodium narcistatin and related compounds
Arizona Board of Regents, a body corporate of the State of Arizona, acting for and on behalf of Arizona State University 1845981*

• Stable oral benzimidazole compsns prepared by non-aqueous layering process
Ranbaxy Laboratories 1845982*

• Ophthalmic compsns and methods of using the same
Bausch & Lomb 1845983*

• Methylpenidate derivatives and uses of them
Institute for Molecular Medicine 1845984*

• Amine derivative containing compsns and methods for the treatment of viral infections related to the etiology of cancer
NexusPharma; Fox Chase Cancer Centre 1845985*

• Substituted fused [1,2]imidazo[4,5-C] ring compounds and methods
Coley Pharmaceutical 1845986*

• Treatment of inflammatory disorders with praziquantel
Gencross 1845987*

• Substituted imidazoquinolines and imidazonaphthyridines
3M Innovative Properties 1845988*

• Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
Progenics Pharmaceuticals 1845989*

• Treatment of metastasised tumours
Novartis Vaccines and Diagnostics 1845990*

• Substituted 5-phenyl pyrimidines I in therapy
BASF 1845991*

• Use of tyrosine kinase inhibitors for the treatment of chronic rhinosinusitis
Boehringer Ingelheim International 1845992*

• Novel adenosine A3 receptor modulators
King Pharmaceuticals Research & Development 1845993*

• Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases
Argenta Discovery 1845994*

• Antibacterial agents
Glaxo Group 1845995*

• Compsns and methods relating to novel compounds and targets thereof
The Regents of the University of Michigan 1845996*

• Apoptosis-inducing antineoplastic silver (I) coordination complexes
Batarseh, Karim 1845997*

• A method for treating neurologic diseases
Pharmacyclics 1845998*

• Use of a fatty acid compsn containing DHA for the production of a medical product or a food stuff for the treatment of amyloidos-related diseases
Pronova Biocare 1845999*

• Pharmaceutical compsns containing bisphosphonate for improving oral absorption
Chong Kun Dang Pharmaceutical 1846000*

• Systems and methods for delivery of peritoneal dialysis (PD) solutions
Fresenius Medical Care Holdings 1846001*

• Method for blood glucose control in a mammal by N-acylated glucosamines
Anastassiades, Tassos 1846002*

• 9A-carbamoyl and thiocarbamoyl azalides with anti-inflammatory activity
GlaxoSmithKline istrazivacki centar Zagreb 1846003*

• New use of dinucleotide polyphosphate derivatives
Imuthes 1846004*

• Kits and improved compsns for treating lower urinary tract
Urigen 1846005*

• Beta-cyclodextrin derivatives as antibacterial agents
Pinnacle Pharmaceuticals 1846006*

• Skin-protective polymer for use in teat care compsns
Kross, Robert 1846007*

• Methods for the mitigation of symptoms of contact lens related dry eye
Johnson & Johnson Vision Care 1846008*

• Improved device for application of medicaments, manufacturing method therefor, and method of treatment
NOLabs 1846009*

• External skin agent comprising modified clay for preventing inflammation
Pola Chemical Industries 1846010*

• Compsn comprising the extract of crude drug complex having neuroprotective activity for preventing and treating stroke and neurodegenerative disease
University-Industry Cooperation Group of Kyung Hee University 1846011*

• Stabilised plant extract and its therapeutic use
Veritron 1846012*

• Treatment of skin diseases
ImmuneRegen BioSciences 1846013*

• Selective delivery of molecules into cells or marking cells in diseased tissue regions using environmentally sensitive trans-membrane protein
The Board of Governors for Higher Education State of Rhode Island and Providence Plantations 1846014*

• Method, compsns and classification for tumour diagnostics and treatment
Zuckerman, Matthew Mark 1846015*

• Methods of increasing cerebral blood flow
The Board of Trustees of the Leland Stanford Junior University 1846016*

• Angiotensin I derivatives
National University of Singapore 1846017*

• Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
Allergan 1846018*

• Methods for treating cardiovascular disease
Eli Lilly 1846019*

• Methods for treating renal cell carcinoma
Novartis Vaccines and Diagnostics 1846020*

• Novel method for treating chronic severe heart failure by using insulin-like growth factor-1 (IGF-1)
Japan as represented by the President of the National Cardiovascular Centre 1846021*

• Methods for treating adhesive capsulitis
Advance Biofractures 1846022*

• A plasmodium vivax hybrid circumsporozoite protein and vaccine
Walter Reed Army Institute of Research 1846023*

• Mycobacterial mutants affecting host apoptosis
Albert Einstein College of Medicine of Yeshiva University 1846024*

• Glycoconjugate vaccines containing peptidoglycan
Nabi Biopharmaceuticals 1846025*

• Anti-cancer DNA vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
The Johns Hopkins University 1846026*

• Improved vaccine against feline calcivirus
Merial 1846027*

• Delivery vehicles, bioactive substance and viral vaccines
Philadelphia Health and Education Corp (d/b/a Drexel University College of Medicine) 1846028*

• Vaccination adjuvants PAM3CYS, poly(I:C), imiquimod, loxoribine, R-848 and CPG-DNA together with MHC I or MUC II epitopes
Johannes Gutenberg-Universitaet Mainz 1846029*

• Fixed doing of HER antibodies
Genentech 1846030*

• Synergistic combination of xolair/omalizumab/E25 with immunosuppressive agent
Novartis 1846031*

• Luca2 and antibodies that bind thereto
Raven Biotechnologies 1846032*

• Blockade of ELR+CXC chemokines as a treatment for inflammatory and autoimmune disease
University of Rochester 1846033*

• Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists
The UAB Research Foundation 1846034*